1-3 of 3
Mark Balk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

David Andorsky, Brittani Wayne, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A. Maglinte, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 7763.
https://doi.org/10.1182/blood-2024-205940
Published: 2024
Journal Articles

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Asher Alban Chanan-Khan, Kirollos S. Hanna, Mei Xue, Marjan Massoudi, Mark Balk, Hossein ZivariPiran, Cecilia Duan, Keri Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2337.
https://doi.org/10.1182/blood-2023-174709
Published: 2023
Journal Articles

Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting

David J Andorsky, Ira Zackon, Thomas W Wilson, Kathleen M Aguilar, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A Maglinte
Journal: Blood
Blood (2023) 142 (Supplement 1): 2413.
https://doi.org/10.1182/blood-2023-172880
Published: 2023